(IN BRIEF) Researchers at The Institute of Cancer Research, London, working with Merck KGaA, have developed the first potent small-molecule inhibitors of DHX8, an enzyme involved in pre-mRNA splicing. The compounds are described as “pathfinder molecules” rather than drug candidates, … Read the full press release
Posted in Business, Germany, Healthcare, Investment, Pharma & Biotech, Science, Technology, United Kingdom
Tagged biochemical tests, cancer biology, cancer diversity, Cancer Drug Discovery, cancer evolution, Cancer Research UK, cancer stress responses, cancer-selective therapeutic window, Centre for Cancer Drug Discovery, chemical probes, compound 53, crystal structure, DEAH-box RNA helicases, DHX8, Dr Rob van Montfort, drug resistance, fragment-based drug design, gene expression, hard-to-drug targets, helicase domain, Hit Discovery and Structural Design Group, HSF1, ICR, ICR and Merck KGaA Advance Fragment-Based Approach to Target DHX8, Journal of Medicinal Chemistry, lung cancer cells, Medicinal Chemistry, Merck KGaA, mRNA splicing, nanomolar concentrations, New Small-Molecule Inhibitors Open Route to Underexplored RNA Helicase Cancer Targets, oncogenes, pathfinder molecules, Pathfinder Molecules Show Potential to Unlock New Family of Cancer Drug Targets, pre-mRNA splicing, protein translation, RNA binding, RNA helicase family, RNA processing, RNA-competitive inhibitors, small molecule inhibitors, spliceosome, structural biology, structure-guided medicinal chemistry, target engagement, The Institute of Cancer Research London, therapeutic cancer targets, underexploited drug targets, X-ray crystallography
(IN BRIEF) Scientists at The Institute of Cancer Research, London have identified features in some aggressive cancer cells that may make them vulnerable to ROCK inhibitors, a group of drugs already used to treat glaucoma. The research found relevant markers … Read the full press release
Posted in Business, Education, Healthcare, Non Profit, Pharma & Biotech, Science, Technology, United Kingdom
Tagged acute myeloid leukaemia, aggressive cancer cells, AML, Barts Cancer Institute, Barts Charity, biomarker discovery, breast cancer, Breast Cancer Now, Breast Cancer Now Toby Robins Research Centre, cancer cell biology, Cancer Cell Shape and Gene Patterns May Help Identify Patients Suitable for Glaucoma Drug Trials, cancer research, Cancer Research UK, cancer spread, cell scaffolding, clinical trials, Dr Simon Vincent, drug repurposing, drug sensitivity database, E-Cadherin, epithelial solid tumours, glaucoma drugs, ICR, ICR Study Opens Path Toward Testing ROCK Inhibitors in Personalised Cancer Treatment, invasive border, iScience, Jaume Barcelo, laboratory validation, melanoma, metastasis, metastatic cancer, molecular fingerprint, mouse studies, NFKB, NHS glaucoma treatment, non-epithelial solid tumours, patient biopsies, personalised cancer treatment, Professor Victoria Sanz Moreno, Queen Mary University of London, Rho kinase, ROCK inhibitors, rounded cancer cells, The Institute of Cancer Research London, treatment resistance, tumour growth, tumour inflammation, tumour invasion, tumour samples, UK Research and Innovation, UKRI, Worldwide Cancer Research
(IN BRIEF) Researchers have identified a previously unknown mechanism that helps melanoma cells spread and resist immunotherapy. The study, published in The EMBO Journal, shows that the protein NGFR activates a pathway involving MLC2, increasing tumour invasiveness while contributing to … Read the full press release
Posted in Education, Healthcare, Non Profit, Pharma & Biotech, Science, Spain, United Kingdom
Tagged advanced melanoma, Barts Charity, biomarker, Blocking NGFR May Help Restore Immunotherapy Sensitivity in Melanoma Models, Breast Cancer Now, cancer biology, Cancer Research UK, cancer spread, cancer treatment, CNB-CSIC, combination treatment, experimental drug, Héctor Peinado, ICR, ICR Scientists Help Identify Potential New Target for Resistant Advanced Melanoma, immune checkpoint therapy, immunotherapy resistance, Madrid, melanoma, metastasis, MLC2, myosin II signalling pathway, myosin light chain 2, nerve growth factor receptor, New Research Uncovers Hidden Mechanism Behind Melanoma Spread and Treatment Resistance, NGFR, oncology, preclinical research, skin cancer, Spain, The EMBO Journal, The Institute of Cancer Research, THX-B, tumour invasion, UK Research and Innovation, United Kingdom, University of London, Victoria Sanz-Moreno, Worldwide Cancer Research
(IN BRIEF) Researchers at The Institute of Cancer Research, London, have developed WIN-DOSE, a proposed clinical-trial design to support more transparent and patient-centred selection of cancer drug doses in early-stage studies. The method enables researchers to establish a clear hierarchy … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, United Kingdom
Tagged cancer drug development, cancer research, Cancer Research UK, Christina Yap, Clinical Cancer Research, clinical trial statistics, clinical trials, dose optimisation, dose selection, Drug Safety, early-stage clinical trials, Emily Alger, ICR, New Statistical Design Aims to Strengthen Evidence-Based Dose Decisions in Cancer Research, oncology, patient-centred research, patient-reported outcomes, Patient-Reported Outcomes Feature in New Framework for Selecting Cancer Drug Doses, pharmacodynamics, pharmacokinetics, precision medicine, The Institute of Cancer Research, treatment efficacy, treatment tolerability, United Kingdom, WIN-DOSE
(IN BRIEF) The Institute of Cancer Research, London, has welcomed the US FDA approval of capivasertib for patients with PTEN-deficient advanced prostate cancer, marking the first regulatory approval of the targeted drug in prostate cancer. Capivasertib blocks AKT, a cancer-driving … Read the full press release
Posted in Business, Education, European Union, Healthcare, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged 3D protein structure, abiraterone, advanced cancer, advanced prostate cancer, AKT inhibitor, AKT pathway, AKT1 mutations, Astex Pharmaceuticals, AstraZeneca, breast cancer, cancer cell growth, cancer cell survival, cancer progression, Cancer Research Technology Limited, Cancer Research UK, CAPItello-281 trial, CAPItello-291 trial, capivasertib, Capivasertib Gains First Prostate Cancer Approval Following Decades of ICR-Led AKT Research, Centre for Cancer Drug Discovery, drug discovery, European Union, FDA, FDA Approval of Capivasertib Marks New Targeted Treatment Option for Advanced Prostate Cancer, fragment-based drug design, fulvestrant, HER2-negative breast cancer, HR-Positive Breast Cancer, ICR, ICR Welcomes FDA Approval of Capivasertib for PTEN-Deficient Advanced Prostate Cancer, ICR Welcomes Milestone FDA Decision for Targeted Therapy in PTEN-Deficient Prostate Cancer, Nature Communications, Nice, oncology research, overall survival, Phase III Trial, PI3 kinase pathway, PIK3CA mutations, precision oncology, Professor Kristian Helin, Professor Paul Workman, prostate cancer patients, prostate cancer treatment, PTEN-deficient prostate cancer, PTEN-deficient tumours, regulatory approval, small molecule inhibitors, targeted therapy, The Institute of Cancer Research, United Kingdom
(IN BRIEF) Thousands of men with early-stage prostate cancer in England will now be offered stereotactic body radiotherapy, also known as stereotactic ablative radiotherapy, through the NHS after results from the PACE-B trial showed the treatment can be as effective … Read the full press release
Posted in Education, Government, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged cancer care, cancer recurrence, cancer treatment, clinical research, Clinical Trials and Statistics Unit, early-stage prostate cancer, England, five-session treatment, gastrointestinal side effects, genital and urinary side effects, high-powered radiotherapy, hospital appointments, ICR, ICR and Royal Marsden Trial Supports Faster Radiotherapy Option for Prostate Cancer Patients, IMRT, intensity-modulated radiotherapy, localised prostate cancer, low-risk prostate cancer, medium-risk prostate cancer, NHS England, NHS England Approves SBRT for Eligible Men with Low and Medium-Risk Prostate Cancer, NHS radiotherapy centres, PACE-B trial, Phase III Trial, precision radiotherapy, Professor Emma Hall, Professor Nicholas van As, Professor Peter Johnson, prostate cancer, radiation beams, radiotherapy, randomised trial, SABR, SBRT, Shorter High-Powered Radiotherapy Course Set to Reduce Treatment Burden for Prostate Cancer Patients, stereotactic ablative radiotherapy, stereotactic body radiotherapy, The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Thousands of Men in England to Benefit from More Precise Five-Visit Prostate Cancer Radiotherapy, treatment side effects, tumour targeting, United Kingdom
(IN BRIEF) Scientists at The Institute of Cancer Research, London, and the University of Oxford have uncovered a mechanism that helps cancer cells survive radiotherapy by repairing radiation-induced DNA damage. The study found that insulin-like growth factor 1 receptor, or … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Balmus Laboratory, Blocking Cancer Cell Repair Pathway May Strengthen Future Radiotherapy Strategies, Cancer and Genome Instability Group, cancer cell survival, cancer research, Cancer Research UK, cancer therapy, cell survival mechanisms, chromatin, combination treatments, DNA damage response, DNA repair, DNA-dependent protein kinase catalytic subunit, DNA-PKcs, double-strand breaks, Dr Matthew Ellis, Dr Valentine Macaulay, drug targets, end-joining, genome instability, growth signalling, ICR, IGF-1R, insulin-like growth factor 1 receptor, Medical Research Council, Molecular Oncology, New Study Links Cancer Growth Receptor to DNA Repair After Radiation Treatment, non-homologous end joining, oncology, precision treatment, Professor Wojciech Niedzwiedz, prostate cancer, Prostate Cancer UK, radiation treatment, radiotherapy, Research Reveals How IGF-1R Helps Tumours Survive Radiation-Induced DNA Damage, resistant tumours, Targeting IGF-1R Could Make Cancer Cells More Vulnerable to Radiotherapy, The Institute of Cancer Research, treatment resistance, tumour biology, United Kingdom, University of Cambridge, University of Oxford
(IN BRIEF) Researchers at The Institute of Cancer Research, London, have published a study in Trials showing that some UK cancer clinical trials may still include eligibility criteria that unintentionally restrict access for underserved patient groups. The study, conducted by … Read the full press release
Posted in Business, Education, Government, Healthcare, Law, Pharma & Biotech, Science, Society, Technology, United Kingdom
Tagged bladder cancer, cancer care, cancer clinical trials, cancer research, cancer treatment access, clinical research barriers, clinical trial eligibility criteria, clinical trial inclusion, Clinical Trials and Statistics Unit, Dr Georgiana Synesi, EDI, equality diversity and inclusion, geographical barriers, head and neck cancer, Health Research Authority, HIV exclusion criteria, ICR, ICR Study Identifies Persistent Barriers to Inclusive Participation in UK Cancer Clinical Trials, ICR-CTSU, INCLUDE Project, inclusive trial design, Institute of Cancer Research Review Highlights How Eligibility Criteria May Limit Access to Cancer Trials, Language Support, medical advances, Medicines and Healthcare products Regulatory Agency, MHRA, multi-centre randomised controlled trials, National Institute for Health and Care Research, New ICR Study Calls for More Inclusive Design of Bladder and Head and Neck Cancer Clinical Trials, NIHR-INCLUDE, oncology research, patient access, patient safety, people living with HIV, personalised cancer research, phase II trials, Phase III Trials, Professor Emma Hall, Rebecca Lewis, The Institute of Cancer Research, trial participation, Trials journal, UK cancer trials, underserved populations
(IN BRIEF) The Institute of Cancer Research, London, has presented encouraging results from the phase Ib/II OrigAMI-4 clinical trial, showing that the targeted immunotherapy drug amivantamab shrank tumours in 42 per cent of patients with recurrent and/or metastatic head and … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged American Society of Clinical Oncology, amivantamab, Amivantamab Demonstrates Encouraging Survival and Tumour Shrinkage Outcomes in Hard-to-Treat Head and Neck Cancer Patients, ASCO Annual Meeting, bispecific monoclonal antibody, cancer research, Carl Walsh, clinical trial, complete response, EGFR, head and neck squamous cell carcinoma, HNSCC, ICR, immunotherapy, Johnson & Johnson, Met, metastatic head and neck cancer, oncology, OrigAMI-4, OrigAMI-5, outpatient cancer treatment, partial response, phase Ib II trial, Phase III Trial, platinum-based chemotherapy, Professor Kevin Harrington, Professor Kristian Helin, recurrent head and neck cancer, Subcutaneous Injection, targeted cancer treatment, Targeted Immunotherapy Injection Shows Strong Clinical Activity in Patients with Treatment-Resistant Head and Neck Cancer, The Institute of Cancer Research and Royal Marsden Team Advance Clinical Evidence for Injectable Head and Neck Cancer Treatment, The Institute of Cancer Research London, The Royal Marsden NHS Foundation Trust, treatment-resistant cancer, tumour shrinkage
(IN BRIEF) A new study led through collaboration between The Institute of Cancer Research, the Karolinska Institute, and Uppsala University has found that some cases of iAMP21, a rare high-risk subtype of paediatric acute lymphoblastic leukaemia, may begin before birth. … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged all®, bone marrow, cancer evolution, Center for Medical Mass Screening in Sweden, childhood cancer research, childhood leukaemia, chromosome 21 amplification, clonal evolution, Dr Gustaf Leijonhufvud, Dr Tony Ford, Dr Viktor Ljungström, Early Detection, genetic alterations, genetic rearrangement, Haematologica, heel prick tests, high-risk leukaemia, iAMP21, ICR, intrachromosomal amplification of chromosome 21, Karolinska Institute, Karolinska University Hospital, London, lymphocytes, May 26 2026, neonatal blood spots, New ICR-Led Research Traces Early Genetic Origins of High-Risk Childhood Leukaemia to Neonatal Blood Samples, New Study Shows Neonatal Blood Spots Can Reveal Early Genetic Alterations Associated with iAMP21 Leukaemia, paediatric acute lymphoblastic leukaemia, paediatric cancer, pre-ALL clone, pre-leukaemic changes, prenatal origins, Professor Britt Gustafsson, Professor Sir Mel Greaves, Researchers Uncover Evidence That Rare Childhood Leukaemia Subtype Can Begin Years Before Diagnosis, Sweden, Swedish Childhood Cancer Society, The Institute of Cancer Research, The Institute of Cancer Research Study Finds Rare Childhood Leukaemia Subtype Can Begin Before Birth, The Institute of Cancer Research Study Finds Rare Childhood Leukaemia Subtype May Originate Before Birth, United Kingdom, Uppsala University
(IN BRIEF) Researchers at The Institute of Cancer Research have published new findings showing that delayed exposure to common microbes may trigger childhood acute lymphoblastic leukaemia (ALL) in genetically susceptible individuals, while early-life microbial exposure may help protect against the … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, Marketing, Science, Technology, United Kingdom
Tagged acute lymphoblastic leukaemia, all®, B-cell development, B-cell precursor ALL, cancer biology, cancer prevention research, Cancer Research UK, childhood cancer prevention, childhood cancer research, childhood immunity, childhood leukaemia, delayed infection hypothesis, Elham Shamsaei, epidemiological studies, ETV6::RUNX1, Experimental Study Supports Long-Standing Theory Connecting Delayed Infections and Childhood ALL, genetic mutations, gut microbiome, Haematologica, ICR, immune system development, immune training, infection timing, inflammatory response, leukaemia risk, microbial exposure, microbiome, paediatric oncology, probiotics, Professor Sir Mel Greaves, Scientists Identify Critical Early-Life Immune Window in Childhood Leukaemia Research, The Institute of Cancer Research
(IN BRIEF) Scientists at The Institute of Cancer Research in London have uncovered new details about how the CDK11 enzyme is activated and regulated, providing insights that could support future cancer drug development. Using cryo-electron microscopy, the team mapped the … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Amy McGeoch, Breakthrough Research Maps Active CDK11 Complex and Its Role in Gene Expression and RNA Splicing, cancer cell growth, cancer research, Cancer Therapies, CDK11, cell division, cellular biology, cryo-electron microscopy, Cryo-EM, cyclin L, cyclin-dependent kinase, Dr Basil Greber, drug development, enzyme regulation, gene expression, gene transcription, ICR, London, Medical Research Council, Molecular Biology, Nature Communications, New Findings from London Researchers Advance Understanding of Cellular Enzyme Involved in Cancer Growth, oncology research, protein complex, pseudo-substrate, RNA splicing, SAP30BP, Scientists Uncover Structural Secrets of CDK11 That Could Support Future Cancer Drug Development, spliceosome, structural biology, The Institute of Cancer Research, therapeutic research
(IN BRIEF) Researchers at The Institute of Cancer Research, London, have found that the precise location of ATRX gene mutations plays a critical role in determining how neuroblastoma tumours behave and respond to treatment. Published in Neoplasia and supported by … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Arcobaleno Cancer Trust, ATRX gene, Cancer Research UK Clinician Scientist Fellowship, childhood cancer, differentiation therapy, Dr Federica Lorenzi, Dr Sally George, ICR, ICR Study Reveals How ATRX Mutation Location Influences Neuroblastoma Treatment Outcomes, Neoplasia, Neuroblastoma, New Research from The Institute of Cancer Research Advances Precision Approach to ATRX-Mutant Neuroblastoma, paediatric oncology, personalised medicine, Siobhans Superstar Legacy, stem cell modelling, The Institute of Cancer Research London, tumour genetics
(IN BRIEF) The Institute of Cancer Research, London has appointed Dr Michelle Harrison to its Board of Trustees, bringing extensive experience in global public policy, corporate leadership, and charity governance to the organisation’s governing body. A former Chief Executive and … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, Science, Technology, United Kingdom
Tagged Big Win Philanthropy, Board of Trustees, Campaign for Science and Engineering, cancer research, charity governance, corporate governance, Dr Michelle Harrison, Dr Michelle Harrison Joins Board of Trustees at The Institute of Cancer Research, ICR, ICR Brings Senior Public Policy and Business Expert onto Board of Trustees, INNOVATION, Involve, leadership, London, Nesta, Professor Dame Julia Buckingham, Public Affairs, public policy, Reykjavik Global Forum, Social Finance UK, STRATEGY, The Institute of Cancer Research London, Verian Group, WPP Group
(IN BRIEF) Researchers at The Institute of Cancer Research, London, have uncovered how the DNA repair enzyme XPF-ERCC1 is recruited to sites of damage and activated inside cells, resolving a long-standing question in molecular biology and providing structural insights that … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AI in science, AlphaFold, Basil Greber, cancer research, cryogenic electron microscopy, DNA damage, DNA repair, genome integrity, ICR, Institute of Cancer Research, Medical Research Council, Molecular Biology, Nature Communications, New Structural Insights into XPF-ERCC1 Could Help Refine Future Cancer Treatments, SLX4, structural biology, XPF-ERCC1
(IN BRIEF) The Institute of Cancer Research has welcomed Sutton Council’s approval of ambitious plans led by Aviva Capital Partners and Socius to create around one million square feet of new life-sciences research and laboratory space across a 12-acre site … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Infrastructure & Utilities, Insurance, Investment, Management, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Aviva Capital Partners, cancer research, Daniel May, economic growth, high-skilled jobs, ICR, ICR Welcomes Approval of New One-Million-Square-Foot Life-Sciences Campus at The London Cancer Hub, Innovation Gateway, Institute of Cancer Research, Kristian Helin, laboratory space, life sciences, London Borough of Sutton, research and development, science infrastructure, Socius, Sophie White, Sutton, The London Cancer Hub, The Royal Marsden NHS Foundation Trust
(IN BRIEF) The Institute of Cancer Research, London, has led the development of OPTIMISE-ROR, the first structured guidance outlining how patient-reported outcomes should be used in early-stage cancer dose-finding trials. Published in the Journal of Clinical Oncology, the recommendations provide … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Cancer Research UK, Christina Yap, clinical trials methodology, dose-finding studies, early-stage cancer trials, Emily Alger, Experimental Cancer Medicine Centre, ICR, Institute of Cancer Research Develops First Foundational Framework for Patient-Reported Outcomes in Early Oncology Trials, Institute of Cancer Research London, International Study Led by ICR Strengthens Role of Patient Experience in Early-Phase Cancer Drug Development, Journal of Clinical Oncology, oncology research, OPTIMISE-ROR, patient-reported outcomes, PROs
(IN BRIEF) Researchers at The Institute of Cancer Research, London, have achieved a breakthrough in the treatment of advanced sarcoma and melanoma through a novel combination of isolated limb perfusion (ILP) and oncolytic virus therapy. In the first clinical trial … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Amgen Pharmaceuticals, cancer research, clinical trial, Dr Lucy Bull Foundation, ICR, ILP, immunotherapy, isolated limb perfusion, Journal for ImmunoTherapy of Cancer, London, Mabs Mardulyn Charitable Foundation, melanoma, NIHR Biomedical Research Centre, oncolytic virus, Professor Alan Melcher, Professor Andrew Hayes, Robert McAlpine Foundation, Royal Marsden Melanoma and Sarcoma Research Fund, sarcoma, Sarcoma UK, T-VEC, talimogene laherparepvec, The Institute of Cancer Research, The Institute of Cancer Research pioneers new dual treatment combining virus therapy and isolated limb perfusion to enhance immune response in advanced cancer, The Royal Marsden NHS Foundation Trust, tumour immunity, United Kingdom, virotherapy
(IN BRIEF) The Phase III RAMPART trial has demonstrated that combining the immunotherapy drugs durvalumab and tremelimumab after surgery significantly improves disease-free survival in patients with early-stage renal cell carcinoma (RCC). Led by the Medical Research Council Clinical Trials Unit … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca UK Limited, cancer recurrence, clinical trial, Combination Therapy, disease-free survival, durvalumab, ESMO 2025, European Society for Medical Oncology, ICR, immunotherapy, kidney cancer, Medical Research Council Clinical Trials Unit, MRC CTU, oncology research, precision medicine, Professor Angela Meade, Professor James Larkin, RAMPART trial, RAMPART trial confirms combination immunotherapy reduces recurrence risk in kidney cancer after surgery, RCC, renal cell carcinoma, The Institute of Cancer Research and Royal Marsden report breakthrough results in renal cancer immunotherapy trial, The Institute of Cancer Research London, The Royal Marsden Cancer Charity, The Royal Marsden NHS Foundation Trust, tremelimumab, UCL, University College London
(IN BRIEF) Long-term data from the international monarchE trial has confirmed that patients with HR+ and HER2- node-positive high-risk early breast cancer achieve better survival outcomes when treated with the targeted therapy abemaciclib in combination with standard hormone therapy. Presented … Read the full press release
Posted in Education, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged abemaciclib, Annals of Oncology, clinical trial, early breast cancer, Eli Lilly and Company, ESMO 2025, European Society for Medical Oncology, HER2 negative, high-risk breast cancer, hormone therapy, HR-positive, ICR, Long-term monarchE study confirms abemaciclib improves survival for high-risk early breast cancer patients, Long-Term Survival, metastatic disease, monarchE trial, National Institute for Health and Care Research, New monarchE data shows first major advance in adjuvant breast cancer survival outcomes in two decades, NIHR, oncology research, Professor Stephen Johnston, targeted therapy, The Institute of Cancer Research London, The Royal Marsden Cancer Charity, The Royal Marsden NHS Foundation Trust
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?